| Symbol | LGND |
|---|---|
| Name | LIGAND PHARMACEUTICALS INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA 92121 |
| Telephone | 858-550-7500 |
| Fax | — |
| — | |
| Website | https://www.ligand.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000886163 |
| Description | Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligands business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The companys revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material. Additional info from NASDAQ: |
2026-05-18 13:01
(80% Positive) LIGAND PHARMACEUTICALS INC (LGND) Announces Business Combination
Read more
2026-05-18 10:07
New Form DEFA14A - LIGAND PHARMACEUTICALS INC <b>Filed:</b> 2026-05-18 <b>AccNo:</b> 0001193125-26-228006 <b>Size:</b> 46 KB
Read more
2026-05-15 01:08
Director KOZARICH JOHN W 🟡 adjusted position in 2.5K shares (2 derivative) of LIGAND PHARMACEUTICALS INC (LGND) at $234.09 Transaction Date: May 01, 2026 | Filing ID: 000049
Read more
2026-05-13 20:09
📋 JOHN KOZARICH (Director) plans to sell 2K shares of LIGAND PHARMACEUTICALS INCORPORATED (at $223.50 each, total $352K) Filed: May 13, 2026 | ID: 004441
Read more
2026-05-12 21:45
📋 JOHN KOZARICH (Director) plans to sell 459 shares of LIGAND PHARMACEUTICALS INCORPORATED (at $224.00 each, total $103K) Filed: May 12, 2026 | ID: 004426
Read more
2026-05-07 11:03
(10% Negative) LIGAND PHARMACEUTICALS INC (LGND) Reports Q2 2026 Financial Results
Read more
2026-05-05 00:20
Reardon Andrew 🟡 adjusted position in 5.0K shares (1 derivative) of LIGAND PHARMACEUTICALS INC (LGND) at $234.02 ($1.7M) Transaction Date: May 01, 2026 | Filing ID: 000046
Read more
2026-05-01 20:16
📋 KOZARICH JOHN W (Director) plans to sell 467 shares of LIGAND PHARMACEUTICALS INC (at $229.87 each, total $107K) Filed: May 01, 2026 | ID: 000485
Read more
2026-04-30 20:41
(99% Neutral) LIGAND PHARMACEUTICALS INC (LGND) Announces Business Combination
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT00002188 | A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma | Phase2 | Sarcoma, Kaposi | Completed | — | — | ClinicalTrials.gov |
| NCT00002212 | A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma | Phase2 | Sarcoma, Kaposi | Completed | — | — | ClinicalTrials.gov |
| NCT00002439 | A Study of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma | Na | Sarcoma, Kaposi | Completed | — | — | ClinicalTrials.gov |
| NCT06385925 | A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS … | Phase1 | Malignant Neoplasm | Recruiting | 2024-04-29 | 2027-04-30 | ClinicalTrials.gov |
| NCT05842785 | TSN222 in Subjects With Advanced Solid Tumors or Lymphomas | Phase1 | Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma | Recruiting | 2023-07-26 | 2026-06-01 | ClinicalTrials.gov |
| NCT05707494 | Lipopolysaccharide Adsorption (Efferon LPS NEO) in Children With Sepsis | Na | Sepsis | Completed | 2023-01-01 | 2025-04-30 | ClinicalTrials.gov |
| NCT05685277 | Bioequivalence Study of Two Formulations of Tablets Ramipril/Hydrochlorothiazid… | Phase1 | Bioequivalence | Completed | 2022-12-28 | 2023-07-31 | ClinicalTrials.gov |
| NCT06386705 | TSN084 Treating Patients With Advanced Malignant Tumors | Phase1 | Malignant Neoplasm | Recruiting | 2022-07-20 | 2026-06-30 | ClinicalTrials.gov |
| NCT05438316 | Bioequivalence Study of Two Formulations of Tablets Ramipril 10 mg in Healthy V… | Phase1 | Bioequivalence | Completed | 2022-06-17 | 2022-11-17 | ClinicalTrials.gov |
| NCT05300438 | Phase I Study of TSN084 in Patients With Advanced Malignant Tumors. | Phase1 | Cancer (With or Without Metastasis) | Active_Not_Recruiting | 2022-02-18 | 2025-06-01 | ClinicalTrials.gov |
| NCT04627831 | Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaire… | Phase2 | Contrast-induced Nephropathy | Withdrawn | 2022-01-01 | 2023-04-01 | ClinicalTrials.gov |
| NCT04827407 | Lipopolysaccharide Adsorption At Septic Shock | Na | Septic Shock | Completed | 2021-03-23 | 2022-08-30 | ClinicalTrials.gov |
| NCT04629976 | Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B | Phase1 | Chronic Hepatitis B | Completed | 2021-01-12 | 2022-12-28 | ClinicalTrials.gov |
| NCT04309526 | Safety, Tolerability and Pharmacokinetics of NCO-48 Fumarate in Healthy Subjects | Phase1 | Hepatitis B | Completed | 2020-03-18 | 2020-10-13 | ClinicalTrials.gov |
| NCT03869983 | Relative Bioavailability of CE-Iohexol (Captisol-enabled™ Iohexol) Injection an… | Na | Contrast-induced Nephropathy | Completed | 2019-04-12 | 2019-06-15 | ClinicalTrials.gov |
| NCT02851849 | A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus | Phase2 | Type 2 Diabetes Mellitus | Completed | 2016-09-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT02672839 | A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 … | Phase1 | Type 2 Diabetes Mellitus (T2DM) | Completed | 2016-02-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT02250222 | Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus | Phase1 | Type 2 Diabetes Mellitus | Completed | 2014-10-01 | 2015-06-01 | ClinicalTrials.gov |
| NCT01919684 | Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics o… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2013-11-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT00879112 | Study of MB07811 in Subjects With Hypercholesterolemia | Phase2 | Hypercholesterolemia | Withdrawn | 2009-04-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00635232 | A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subject… | Phase2 | Hypertension | Completed | 2008-03-01 | 2008-12-01 | ClinicalTrials.gov |
| NCT00940953 | Compare Captisol-Enabled (CE) Budesonide + Azelastine Nasal Solution and Rhinoc… | Phase2 | Seasonal Allergic Rhinitis | Completed | 2008-02-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00626418 | The Effects of Aplindore on the Treatment of Signs and Symptoms of Restless Leg… | Phase2 | Restless Legs Syndrome | Completed | 2008-02-01 | — | ClinicalTrials.gov |
| NCT00623324 | The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's … | Phase2 | Early Stage Parkinson's Disease | Completed | 2008-01-01 | — | ClinicalTrials.gov |
| NCT00522925 | A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension | Phase2 | Hypertension | Completed | 2007-08-01 | 2008-05-01 | ClinicalTrials.gov |
| NCT00458016 | Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients Wi… | Phase2 | Type 2 Diabetes Mellitus | Completed | 2007-03-01 | 2008-03-01 | ClinicalTrials.gov |
| NCT00938613 | Compare CE-Budesonide Nasal Solution & Rhinocort Aqua in an EEC Study of AR | Phase2 | Seasonal Allergic Rhinitis | Completed | 2007-02-01 | 2007-04-01 | ClinicalTrials.gov |
| NCT00125372 | Study of Tarceva and Targretin in Stage I-II Lung Cancer | Na | Carcinoma, Non-small-cell Lung | Completed | 2005-12-01 | 2010-08-01 | ClinicalTrials.gov |
| NCT00125359 | Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Can… | Phase2 | Carcinoma, Non-small-cell Lung | Completed | 2005-08-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT00674453 | The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Ev… | Phase2 | Bone Loss | Completed | 2004-09-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00143273 | Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis -… | Phase2 | Osteoporosis | Completed | 2004-06-01 | 2006-03-01 | ClinicalTrials.gov |
| NCT00238628 | A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Tr… | Phase1 | Lung Cancer | Completed | 2004-04-01 | 2005-12-01 | ClinicalTrials.gov |
| NCT00151008 | Bexarotene With Narrow-Band UVB for Psoriasis | Phase2 | Psoriasis | Completed | 2003-11-01 | 2005-08-01 | ClinicalTrials.gov |
| NCT00073736 | Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectab… | Phase1 | Hepatocellular Carcinoma | Completed | 2003-09-01 | — | ClinicalTrials.gov |
| NCT00163137 | Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of Thes… | Phase3 | Osteoporosis | Completed | 2003-05-01 | 2005-10-01 | ClinicalTrials.gov |
| NCT00063076 | Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopeci… | Phase2 | Alopecia Areata | Completed | 2003-05-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT01116622 | Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancer… | Phase1 | Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus) | Completed | 2003-04-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT00306969 | Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cut… | Phase1 | Cutaneous T-Cell Lymphoma | Completed | 2001-12-01 | 2004-04-01 | ClinicalTrials.gov |
| NCT00141323 | Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL) | Phase3 | Osteoporosis | Completed | 2001-11-01 | 2007-12-01 | ClinicalTrials.gov |
| NCT00153842 | A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsu… | Phase1 | Carcinoma, Non-small-cell Lung | Terminated | 2001-08-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00211198 | Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) | Phase4 | Lymphoma, T-Cell, Cutaneous | Completed | 2001-05-01 | 2006-01-01 | ClinicalTrials.gov |
| NCT00322296 | Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients W… | Phase2 | Parapsoriasis | Terminated | 2001-04-01 | 2004-08-01 | ClinicalTrials.gov |
| NCT00006345 | Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persist… | Phase2 | Drug/Agent Toxicity by Tissue/Organ | Completed | 1999-11-01 | 2004-03-01 | ClinicalTrials.gov |
| NCT00003752 | Bexarotene in Treating Patients With Metastatic Breast Cancer | Phase2 | Breast Cancer | Completed | 1998-10-01 | 2003-03-01 | ClinicalTrials.gov |
Total clinical trials: 44
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo (Captisol®) | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT01919684 |
| LGD-6972 | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT01919684 |
| Placebo (Captisol ®) | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT02250222 |
| LGD-6972 | Other | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT02250222 |
| LGD-6972 Capsules | Other | Phase PHASE1 | Type 2 Diabetes Mellitus (T2DM) | COMPLETED | NCT02672839 |
| LGD-6972 Solution | Other | Phase PHASE1 | Type 2 Diabetes Mellitus (T2DM) | COMPLETED | NCT02672839 |
| Placebo | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT02851849 |
| LGD-6972-15 mg | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT02851849 |
| LGD-6972-10 mg | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT02851849 |
| LGD-6972-5 mg | Other | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT02851849 |
| CE-Iohexol | Other | Approved | Contrast-induced Nephropathy | COMPLETED | NCT03869983 |
| Omnipaque™ (iohexol) Injection | Other | Approved | Contrast-induced Nephropathy | COMPLETED | NCT03869983 |
| Placebo | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT04309526 |
| NCO-48 Fumarate | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT04309526 |
| Iohexol | Other | Phase PHASE2 | Contrast-induced Nephropathy | WITHDRAWN | NCT04627831 |
| CE-Iohexol | Other | Phase PHASE2 | Contrast-induced Nephropathy | WITHDRAWN | NCT04627831 |
| Tenofovir Alafenamide 25 mg | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT04629976 |
| NCO-48 Fumarate 20 mg | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT04629976 |
| NCO-48 Fumarate 4 mg | Other | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT04629976 |
| Tritace® tablet 10 mg | Other | Phase PHASE1 | Bioequivalence | COMPLETED | NCT05438316 |
| Ramipril tablet 10 mg | Other | Phase PHASE1 | Bioequivalence | COMPLETED | NCT05438316 |
| Erlotinib (Tarceva™) | Other | Phase PHASE1 | Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus) | COMPLETED | NCT01116622 |
| Bexarotene (Targretin®) | Other | Phase PHASE1 | Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus) | COMPLETED | NCT01116622 |
| Tritace® Plus tablet 10 mg/25 mg | Other | Phase PHASE1 | Bioequivalence | COMPLETED | NCT05685277 |
| Ramipril/Hydrochlorothiazide tablet 10 mg/25 mg | Other | Phase PHASE1 | Bioequivalence | COMPLETED | NCT05685277 |
| TSN084 | Other | Phase PHASE1 | Cancer (With or Without Metastasis) | ACTIVE_NOT_RECRUITING | NCT05300438 |
| TSN084 | Other | Phase PHASE1 | Cancer (With or Without Metastasis) | ACTIVE_NOT_RECRUITING | NCT05300438 |
| TSN084 | Other | Phase PHASE1 | Cancer (With or Without Metastasis) | ACTIVE_NOT_RECRUITING | NCT05300438 |
| TSN084 | Other | Phase PHASE1 | Malignant Neoplasm | RECRUITING | NCT06386705 |
| TSN084 | Other | Phase PHASE1 | Malignant Neoplasm | RECRUITING | NCT06386705 |
| Phase II-solid tumors or lymphomas | Other | Phase PHASE1 | Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma | RECRUITING | NCT05842785 |
| Phase II-Advanced melanoma | Other | Phase PHASE1 | Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma | RECRUITING | NCT05842785 |
| Phase II-HNSCC | Other | Phase PHASE1 | Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma | RECRUITING | NCT05842785 |
| Phase I dose escalation | Other | Phase PHASE1 | Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma | RECRUITING | NCT05842785 |
| Phase II-solid tumors or lymphomas | Other | Phase PHASE1 | Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma | RECRUITING | NCT05842785 |
| Phase II-Advanced melanoma | Other | Phase PHASE1 | Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma | RECRUITING | NCT05842785 |
| Phase II-HNSCC | Other | Phase PHASE1 | Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma | RECRUITING | NCT05842785 |
| Phase I dose escalation | Other | Phase PHASE1 | Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma | RECRUITING | NCT05842785 |
| Efferon LPS hemoperfusion | Other | Approved | Septic Shock | COMPLETED | NCT04827407 |
| Efferon LPS NEO | Other | Approved | Sepsis | COMPLETED | NCT05707494 |
| TSN1611 | Other | Phase PHASE1 | Malignant Neoplasm | RECRUITING | NCT06385925 |
| TSN1611 | Other | Phase PHASE1 | Malignant Neoplasm | RECRUITING | NCT06385925 |
| TSN1611 | Other | Phase PHASE1 | Malignant Neoplasm | RECRUITING | NCT06385925 |
| TSN1611 | Other | Phase PHASE1 | Malignant Neoplasm | RECRUITING | NCT06385925 |
| TSN1611 | Other | Phase PHASE1 | Malignant Neoplasm | RECRUITING | NCT06385925 |
| TSN1611 | Other | Phase PHASE1 | Malignant Neoplasm | RECRUITING | NCT06385925 |
| TSN1611 | Other | Phase PHASE1 | Malignant Neoplasm | RECRUITING | NCT06385925 |
| TSN1611 | Other | Phase PHASE1 | Malignant Neoplasm | RECRUITING | NCT06385925 |
| TSN1611 | Other | Phase PHASE1 | Malignant Neoplasm | RECRUITING | NCT06385925 |
| TSN1611 | Other | Phase PHASE1 | Malignant Neoplasm | RECRUITING | NCT06385925 |
| TSN1611 | Other | Phase PHASE1 | Malignant Neoplasm | RECRUITING | NCT06385925 |
| TSN1611 | Other | Phase PHASE1 | Malignant Neoplasm | RECRUITING | NCT06385925 |
| TSN1611 | Other | Phase PHASE1 | Malignant Neoplasm | RECRUITING | NCT06385925 |
| TSN1611 | Other | Phase PHASE1 | Malignant Neoplasm | RECRUITING | NCT06385925 |
| Secnidazole 2 GM Oral Granules | DRUG | Phase PHASE2 | Recurrent Bacterial Vaginosis | COMPLETED | NCT05033743 |
| SLN12140 | DRUG | Phase PHASE1 | Healthy Volunteer | NOT_YET_RECRUITING | NCT06945445 |
| TSN1611 | DRUG | Phase PHASE1 | Malignant Neoplasm | RECRUITING | NCT06385925 |
| Tenofovir Alafenamide 25 mg | DRUG | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT04629976 |
| NCO-48 Fumarate 20 mg | DRUG | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT04629976 |
| NCO-48 Fumarate 4 mg | DRUG | Phase PHASE1 | Chronic Hepatitis B | COMPLETED | NCT04629976 |
| Iohexol | DRUG | Phase PHASE2 | Contrast-induced Nephropathy | WITHDRAWN | NCT04627831 |
| NCO-48 Fumarate | DRUG | Phase PHASE1 | Hepatitis B | COMPLETED | NCT04309526 |
| CE-Iohexol | DRUG | Phase PHASE2 | Contrast-induced Nephropathy | WITHDRAWN | NCT04627831 |
| Omnipaque™ (iohexol) Injection | OTHER | Approved | Contrast-induced Nephropathy | COMPLETED | NCT03869983 |
| LGD-6972-15 mg | DRUG | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT02851849 |
| LGD-6972-10 mg | DRUG | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT02851849 |
| LGD-6972-5 mg | DRUG | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT02851849 |
| LGD-6972 Capsules | DRUG | Phase PHASE1 | Type 2 Diabetes Mellitus (T2DM) | COMPLETED | NCT02672839 |
| LGD-6972 Solution | DRUG | Phase PHASE1 | Type 2 Diabetes Mellitus (T2DM) | COMPLETED | NCT02672839 |
| Placebo (Captisol ®) | DRUG | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT02250222 |
| Placebo (Captisol®) | DRUG | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT01919684 |
| LGD-6972 | DRUG | Phase PHASE1 | Type 2 Diabetes Mellitus | COMPLETED | NCT02250222 |
| Erlotinib (Tarceva™) | DRUG | Phase PHASE1 | Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus) | COMPLETED | NCT01116622 |
| Bexarotene (Targretin®) | DRUG | Phase PHASE1 | Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus) | COMPLETED | NCT01116622 |
| Budesonide + Azelastine | DRUG | Phase PHASE2 | Seasonal Allergic Rhinitis | COMPLETED | NCT00940953 |
| Budesonide | DRUG | Phase PHASE2 | Seasonal Allergic Rhinitis | COMPLETED | NCT00938613 |
| MB07811 | DRUG | Phase PHASE2 | Hypercholesterolemia | WITHDRAWN | NCT00879112 |
| raloxifene | DRUG | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00163137 |
| Lasofoxifene | DRUG | Phase PHASE2 | Bone Loss | COMPLETED | NCT00674453 |
| irbesartan | DRUG | Phase PHASE2 | Hypertension | COMPLETED | NCT00635232 |
| Aplindore | DRUG | Phase PHASE2 | Restless Legs Syndrome | COMPLETED | NCT00626418 |
| PS433540 | DRUG | Phase PHASE2 | Hypertension | COMPLETED | NCT00635232 |
| Placebo | OTHER | Phase PHASE1 | Healthy Volunteer | NOT_YET_RECRUITING | NCT06945445 |
| MB07803 | DRUG | Phase PHASE2 | Type 2 Diabetes Mellitus | COMPLETED | NCT00458016 |
| Bexarotene 1% gel | DRUG | Phase PHASE2 | Parapsoriasis | TERMINATED | NCT00322296 |
| Iressa | DRUG | Phase PHASE1 | Lung Cancer | COMPLETED | NCT00238628 |
| ONTAK (denileukin difitox, DAB389IL-2) | DRUG | Phase PHASE4 | Lymphoma, T-Cell, Cutaneous | COMPLETED | NCT00211198 |
| Bexarotene/NBUVB vs placebo NBUVB | DRUG | Phase PHASE2 | Psoriasis | COMPLETED | NCT00151008 |
| placebo | DRUG | Phase PHASE2 | Hypertension | COMPLETED | NCT00635232 |
| lasofoxifene | DRUG | Phase PHASE3 | Osteoporosis | COMPLETED | NCT00163137 |
| erlotinib (Tarceva) and bexarotene (Targretin) | DRUG | Approved | Carcinoma, Non-small-cell Lung | COMPLETED | NCT00125372 |
| erlotinib and bexarotene | DRUG | Phase PHASE2 | Carcinoma, Non-small-cell Lung | COMPLETED | NCT00125359 |
| MB07133 2400 mg/m2/day | DRUG | Phase PHASE1 | Hepatocellular Carcinoma | COMPLETED | NCT00073736 |
| MB07133 1800 mg/m2/day | DRUG | Phase PHASE1 | Hepatocellular Carcinoma | COMPLETED | NCT00073736 |
| MB07133 1200 mg/m2/day | DRUG | Phase PHASE1 | Hepatocellular Carcinoma | COMPLETED | NCT00073736 |
| MB07133 600 mg/m2/day | DRUG | Phase PHASE1 | Hepatocellular Carcinoma | COMPLETED | NCT00073736 |
| MB07133 300mg/m2/day | DRUG | Phase PHASE1 | Hepatocellular Carcinoma | COMPLETED | NCT00073736 |
| Targretin Gel 1% | DRUG | Phase PHASE2 | Alopecia Areata | COMPLETED | NCT00063076 |
| dexamethasone | DRUG | Phase PHASE2 | Drug/Agent Toxicity by Tissue/Organ | COMPLETED | NCT00006345 |
| denileukin diftitox | BIOLOGICAL | Phase PHASE2 | Drug/Agent Toxicity by Tissue/Organ | COMPLETED | NCT00006345 |
| bexarotene | DRUG | Phase PHASE2 | Breast Cancer | COMPLETED | NCT00003752 |
| Bexarotene | DRUG | Phase PHASE1 | Lung Cancer | COMPLETED | NCT00238628 |
| Alitretinoin | DRUG | Approved | Sarcoma, Kaposi | COMPLETED | NCT00002439 |
Total products: 103